LYFE Therapeutics – A new therapy for chronic liver inflammation and fibrosis
Fibrotic disorders are an increasing cause of morbidity and mortality worldwide contributing to approx. 45% of deaths in the developed world. A major cause of liver fibrosis is NASH, a severe form of the metabolic condition non-alcoholic fatty liver disease (NAFLD).